Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation Message Board

  • end2war end2war Jul 7, 2014 2:56 PM Flag

    New Promotional Brochure by MC discusses Imetelstat Breakthru

    htXtp:/X/XwXwX.mayo.Xedu/pmts/mc7300-mc7399/mc7323.pXdf
    REMOVE ALL X

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • End has been wrong with just about EVERYTHING he has posted.

      He is simply full of BS.

      Of course, IMO.

    • Mayo clinic was the #1 hospital in the new 2014 US and World Report. Just saying.

    • Same old document from March. Why do you say it's new?

    • STOPPING HEMATOLOGICAL CANCER:
      New Drug Induces Remissions in Myelofibrosis
      The results of a Mayo Clinic study demonstrate that
      a drug named imetelstat induces remissions in some
      patients with myelofibrosis. This is a form of chronic
      leukemia that affects the patient’s bone marrow
      that is replaced by fibrosis (scar tissue) instead
      of blood-producing cells.
      Scientists do not yet know the exact mechanism of
      acttion for imetelstat, but believe it interferes with the
      survival and proliferation of cancer cells by inhibiting
      a critical enzyme called telomerase. One of the functions
      of telomerase is to repair the ends of chromosomes
      called telomeres, and because cancer cells have shorter
      than normal telomere size, they are particularly susceptible
      to the drug.
      The study results are promising. Some patients
      participating in the clinical trial taking imetelstat obtained
      dramatic responses, and we have seen some complete
      responses (tantamount to a cure), which is almost
      unheard of in this disease.
      THE NEED TO DISCOVER, IMPROVE, AND ADVANCE
      Research is the fundamental reason that people across
      the globe are living longer, healthier lives.
      Mayo Clinic applies basic science to unlock the
      destructive secrets of cells and discover how to repair
      or reverse the damage. We then translate that knowledge
      into first-time cures and treatments for a wide range
      of life-threatening diseases and chronic conditions.
      Patients receive research-driven care at Mayo Clinic,
      which possesses a long legacy of providing a
      team-based approach to integrating patient care,
      research, and education.
      9 UNLOCKING THE SECRETS OF CELLS • MAYO CLINIC BIOMEDICAL RESEARCH
      Although patients may experience relief in response
      to other treatments, their bone marrow does not
      usually return to normal. But in the case of this new
      therapy, some of the patients participating in the trial
      developed normal bone marrow.
      Researchers studied imetelstat in 33 patients at
      Mayo Clinic and have now followed the first 22 patient

    • remove all x AND add w

      • 1 Reply to imetelstat
      • MAYO CLINIC
        BIOMEDICAL
        RESEARCH
        9
        UNLOCKING THE SECRETS OF CELLS •
        MAYO CLINIC BIOMEDICAL RESEARCH
        But more breakthroughs are necessary for our patients.
        We need to better understand and more effectively treat
        diseases ranging from the most prevalent like cancer
        to the rarest disorders. In such spectrum of diseases,
        we need to know why communication between cells
        breaks down.
        Generous donors enable Mayo Clinic to spearhead
        the most advanced research and offer hope to patients
        around the globe in the form of new treatments and
        technologies. By investing in Mayo’s research programs,
        benefactors contribute to developing faster treatments
        and cures for patients who need them now.
        Research is the fundamental reason that people across
        the globe are living longer, healthier lives.
        Mayo Clinic applies basic science to unlock the
        destructive secrets of cells and discover how to repair
        or reverse the damage. We then translate that knowledge
        into first-time cures and treatments for a wide range
        of life-threatening diseases and chronic conditions.
        Patients receive research-driven care at Mayo Clinic,
        which possesses a long legacy of providing a
        team-based approach to integrating patient care,
        research, and education.
        THE NEED TO DISCOVER, IMPROVE, AND ADVANCE
        The results of a Mayo Clinic study demonstrate that
        a drug named imetelstat induces remissions in some
        patients with myelofibrosis. This is a form of chronic
        leukemia that affects the patient’s bone marrow
        that is replaced by fibrosis (scar tissue) instead
        of blood-producing cells.
        Scientists do not yet know the exact mechanism of
        action for imetelstat, but believe it interferes with the
        survival and proliferation of cancer cells by inhibiting
        a critical enzyme called telomerase. One of the functions
        of telomerase is to repair the ends of chromosomes
        called telomeres, and because cancer cells have shorter
        than normal telomere size, they are particularly susceptible
        to the drug.
        The study results are promising. Some patient

    • Yes the Mayo Clinic is bragging about GERN's miracle.
      Monday is GERN's day.

      Sentiment: Strong Buy

    • End, you have provided a good layman's explanation of the neoplasm disorder (under Joanie's response in here). Scientifically, gene mutation causes the onset of inbalance and the disease spreads as cancer cells produced by the mutation multiply a lot faster than the normal ones in the blood. The process of cancer-cell multiplication is terminated when the telomeres at the ends of the chromosomes are stopped from growing. I understand, by depriving them of the telomerase. My understanding is that Imetelstat is effective in doing this. Thus, with growth of cancer cells curtailed, the proportion of normal cells in the blood grows again and the blood becomes normal when all cancer cells die. However, my puzzle and questions are related to what happens to the gene-mutation process? Was that just a one-time occurrence that disappears when all cancer cells die? Does Imetelstat work only in obliterating supply of telomerase to cancer-cell telomeres or goes beyond that and repairs also damage to chromosomes? Irish's post below suggests that it does that too! But, then, the question remains as to how it does that, and if that process causes any other undesirable side effect? Does the LFT abnormality have anything to do with such a side effect and why? I think that is where the FDA's concern may lie. A detailed genomic study may also be in order. All this study is apparently too much for the current scientific-investigation capability and staffing of Geron because its management seems to be focused elsewhere! Therefore, I consider it inept. Luckily, we have Mayo and Tefferi to help in this regard; but, collaboration with a resourceful and compatible partner may become a necessity. This is neither Scarlett's nor Huh's cup of tea!!

      Since this a Yahoo board, I think it will be wise to go no further deeper into this matter. Thanks for your detailed reply.

      • 4 Replies to mruyog
      • Yog, few people here get it. Imetelstat is not a drug for treating liver function disorders, and if patients receiving imetelstat already have poor liver function test results prior to treatment, then we would not expect that to improve much following treatments. Except that we know that it did help reduce an enlarged liver in one patient. This could indicate some positive results regarding liver health, but it is not mentioned here in discussions. If we were to have data that all patients who receive imetelstat have good liver funtion test results prior to receiving imetelstat, and in a few weeks or months, we begin to see poor liver function test results, then we have the manipulated variable isolated. Otherwise, it is just a poorly designed experiment and it does not allow us to isolate a cause. No reporters are telling anyone this fact. It is clear to me that right now we do not have good baseline data on liver funtion prior to IV treatments of imetelstat for the FDA to say imetelstat is the causitive agent of liver function disorders. Maybe the Mayo Clinic has it, but it could be that the FDA did not ask for it when the Mayo Clinic initiated its trial and so the baseline data are largely missing?

        Sentiment: Hold

      • Yog, whew! If I were with the FDA, I would be wanting to see the baseline data on what the liver funtion was like prior to treatment with imetelstat, because Geron tends to get the refractory patients that have been treated wtih other drugs! How did those drugs affect their liver function? No FDA official should ignore such facts; it is quite important to know what liver function tests results were prior to any treament with a new drug. Also, during treatment with imetelstat there could be immune system problems due to the fact that it is an immuno-suppressive drug, which might allow for endotoxin build up (the average healthy person has about 6 pounds of microbes in and on his/her body), and thus affect liver fuction. A single bacterium can grow from one to 2 followed by 17 zeros in about 24 hours. Also, I would look at hyperbilirubinemia and say did you try to treat patients with this disorder, upon discovery, with light? Why not? Moreover, one would hope that the FDA staff understand statistics well enough to know that 8-10 patients with similar disorders does not really tell us much without far more information gathered from a larger group of patients with similar neoplasm disorders. They should know about continuous random variables with such patients aside from the small number of them. One has to know liver function test results at the beginning, especially with other treatments being common for patients coming in for imetelstat.

        Sentiment: Hold

      • Mr, What you call "the gene mutation process" must be better understood. My question is how does it happen that gene's mutate to create known types of mutation that are classified, such as Jak2. That the mechanism of mutation is not entirely random forces a search for what causes the types of mutations that occur, or makes them more or less likely to happen. I am not familiar with the mutation process, but I am assuming that for any of the mutation types to take hold and alter the normal cells, their must be a significant tendency to generate the specific mutation and it must occur frequently to overcome the cell blueprint. I think it is Darwinian to some extent as certain mutations have advantages and they survive in an adverse environment

        There is a lot of effort ongoing to classify types of mutations. Apparently there is a catelog of most likely or possible mutations and different ones lead to different health problems. At the stage medicine is in, they are listing the mutations, and defining their characteristics, but they are not far along on understanding the gene mutation process in the sense of understanding its causes. Some macro causes, like smoking are known, but what about the micro causes, those that occur chemically. How are those stopped or undone; and if you do stop it, will it be a temporary stop or not. What is necessary to undo the conditions that lead to the mutation process?

        If Imetelstat can block telomerase and stop neoplasm growth that has begun, and if the normal stem cells can fight back to gain control and restore blood balance, then how do you keep things that way so the aberrant conditions will not recur? Do you keep giving Imetelstat or what do you do to change the condition that started the disease in the first place? Or do you need to do anything once you restore normalcy? Can the bodies natural systems keep the blood balanced once the neoplasm is stopped and driven out?

      • We know the stuff works, testimonials by patients are real, truthful and honest. The simple truth is that the data requested by the FDA should have been available by the push of the enter button on a PC. The data not being available demonstrates that the skills of Geron Management are questionable. Let me see if I have this correct, you have been running FDA approved trials for 2 + years, you know the parameters of the information that you must provide to the FDA and you do not keep those records. They deserve to be sued. Unfortunately, we the stock holders are the ones who pay for it and the patients who need this miracle drug. When I lose my investment due to incompetency that makes it even worse and I get really xxxxxx. Scarlett, sell the company, supposedly this is your skill set. At the very least and with the information you have from MC, you should be able to get at least 18 to $24 a share. its worth that even with the hold. Incompetency does not even begin to describe these folks. Oh and lets not forget, every little dog and pony show that comes up, Las Vegas, New York, ETC. Scarlett attends at company expense instead of staying in the home office and turning on the after burners to obtain the information that the FDA seeks to get this hold lifted. IMHO, of course and I did not participate in any of the class action stuff. I'm just xxxxxx, its been long enough.

    • Thank you end. Unfortunately I doubt you learned of this important information on GERN's website or in a published article in the wall street journal paid for by GERN.
      Scarlett believes in the old rule Silence is golden.
      Good luck with GERN

    • Thanks for the info...great stuff...

    • end - thank you. I am looking forward to the new edition of the brochure! The one that could inform readers as to the new JAK2+ MF remissions, the cytogenetic remissions (e.g. chromosome damage repair), the now known mechanisms of action (e.g. genetic architecture), the success with other blood cancers, and the promising applications in other non blood cancers with splicing mutations - IMO.

    • View More Messages
 
GERN
2.66-0.04(-1.48%)Jul 22 4:00 PMEDT